Scientists have developed what they called “virus cocktails” Fight superbugs In a major advance for infectious disease treatment.
In the researcher of the University and Alfred Melbourne, AustraliaA product has developed a bacterial virus, known as ‘bacteriophage’, to compete Antimicial resistant bacteria.
Treatment named Enllyi-02 is a five-phase cocktail, especially designed to target the entraobactor CloseK Complex (ECC), which is a group of bacteria responsible for severe, low healing infections.
Professor Jeremy J. Berr said, “This is the first time we have designed and developed a diagnostic-taiyar phase therapy product to suit AMR bacterial pathogen in a local hospital.” Nature microbiology,
“Enlilli-02 is not just a scientific achievement, it is a clinical device designed for frontline use against deadly, drug resistant, bacterial pathogens.”
Antarobactor is very difficult to treat infections and is associated with over 200,000 deaths globally in 2019.
They have emerged in hospitals around the world and have the ability to develop resistance for many of the last-line antibiotics.
“Antibiotic resistance is one of the biggest challenges in modern medicine,” said Professor Barr. “With Enllyli-02, we are showing that phase therapy may be ready for accurate, powerful and clinical deployment.”
Using a decade bacterial isolates, the lead author on the study. Dinesh Subedi said that the research team developed and produced entellli-02 through a rigorous process of phase isolation, genetics and pregnancy testing.
“We initially started with three stages in our cocktails, but through a repetitive design, we improved the cocktail by genetically adopting the virus to expand our host boundaries, followed by two additional stages with better treatment results,” Dr. Sabdi said.
“Final product, Enllyli-02, consists of five stages that can kill a wide range of antobractor isolates and reduce the weight of bacteria in infected mice more than 99 percent.”
The team is now ready with a “off-chest product” to support the treatment of some of the most difficult infections.
This drug comes after the infection rate from the resistant “nightmare BacteriaAccording to a recent report, there was an increase of about 70 percent between 2019 and 2023. Centers for Disease Control and Prevention (CDC) Scientist.
Bacteria that is difficult to treat due to a particular gene, mainly increased growth, CDC Researchers wrote in an article published last Monday Internal medicine name,
Researchers stated that only two antibiotics work against those infections, and drugs are expensive and should be administered through IV.
Bacteria with so -called NDM genes were once considered foreign, and were associated with a small number of patients receiving medical care abroad. Although the number is still small, the rate of US cases jumped more than five times in recent years, the researchers reported.
“The rise of NDMS in the US is a serious threat and is very worrying,” David Weiss said, A. Amori university Infectious disease researcher.
CDC scientists said that many people are unfamiliar carriers of drug -resistant bacteria, which can lead to the spread of the community.